AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16984757 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial cycles with oral oestradiol and vaginal oestradiol if needed
Number of subjects: 163
Study 16984757 — intervention group
Group type: COMPARATOR
Intervention: Stimulated cycles with recombinant FSH and human gonadotrophin hormone injection
Number of subjects: 163
Study 16984757 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial cycles switched to vaginal oestradiol
Number of subjects: 163
Study 14626627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 21
Study 14626627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude increments of 2 dB or more
Number of subjects: 8
Study 10790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude decrements of 3 dB or more
Number of subjects: 8
Study 10790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of second formant frequency (from perceived /u/ to perceived /i/) with amplitude increments
Number of subjects: 8
Study 10790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of second formant frequency (from perceived /u/ to perceived /i/) with amplitude decrements
Number of subjects: 8
Study 10790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral change with small amplitude change
Number of subjects: 8
Study 9493920 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (6 hours of training in sleep hygiene and relaxation)
Number of subjects: 26
Study 9493920 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy with occasional hypnotics
Number of subjects: 26
Study 9493920 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy without hypnotics
Number of subjects: 26
Study 9493920 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 26
Study 8348061 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (10 mg/day)
Number of subjects: 0
Study 8348061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2951803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 17
Study 2951803 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (fenoterol 200 micrograms plus ipratropium bromide 80 micrograms)
Number of subjects: 17
Study 2951803 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 17
Study 30326954 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium breve Bb99 2 × 108 cfu, Propionibacterium freundenreichii subsp. shermanii JS 2 × 109 cfu, Lactobacillus rhamnosus Lc705 5 × 109 cfu, Lactobacillus rhamnosus GG 5 × 109 cfu)
Number of subjects: 199
Study 30326954 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 199
Study 25730596 — intervention group
Group type: EXPERIMENTAL
Intervention: EX + SUPP (combined home‐based exercise and calcium and vitamin D supplements)
Number of subjects: 43
Study 25730596 — intervention group
Group type: COMPARATOR
Intervention: SUPP (calcium and vitamin D supplements alone)
Number of subjects: 43
Study 25539582 — intervention group
Group type: EXPERIMENTAL
Intervention: DOiT intervention
Number of subjects: 1486
Study 24006671 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture at regional + distal acupoints
Number of subjects: 76
Study 24006671 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular EA
Number of subjects: 76
Study 24006671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting at Taiyang (EX‐HN 5) + Ashi points
Number of subjects: 76
Study 24006671 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture or EA stimulation
Number of subjects: 76
Study 24006671 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture therapy
Number of subjects: 76
Study 24006671 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture stimulation (control for F2)
Number of subjects: 76
Study 24006671 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture stimulation (control for F3)
Number of subjects: 76
Study 24006671 — intervention group
Group type: COMPARATOR
Intervention: No bloodletting (control for F4)
Number of subjects: 76
Study 21347978 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet chat groups
Number of subjects: 152
Study 21347978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no internet chat groups)
Number of subjects: 152
Study 18163485 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (70 mg, 210 mg, or 630 mg single doses; 3 doses of 70 mg, 3 doses of 210 mg, or 7 doses of 420 mg repeated doses)
Number of subjects: 73
Study 18163485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 16389028 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute chorioamnionitis
Number of subjects: 227
Study 16389028 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic chorioamnionitis
Number of subjects: 227
Study 14636465 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (Rab) 10mg twice daily for two days
Number of subjects: 30
Study 14636465 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (Ome) 20mg twice daily for two days
Number of subjects: 30
Study 14636465 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (Rab)
Number of subjects: 30
Study 14636465 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (Ome)
Number of subjects: 30
Study 10805610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaethylene (0.25 or 0.5 mg/kg)
Number of subjects: 0
Study 10805610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0.25 or 0.5 mg/kg)
Number of subjects: 0
Study 10805610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10805610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaethylene
Number of subjects: 0
Study 10805610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 0
Study 8927664 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 0
Study 8927664 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethylimipramine
Number of subjects: 0
Study 1817902 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 0.001%
Number of subjects: 0
Study 1817902 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.005%
Number of subjects: 0
Study 1817902 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional stress (injection, tooth extraction)
Number of subjects: 0
Study 6787721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gold formulation at 4 mg/d
Number of subjects: 22
Study 6787721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gold formulation at 6 mg/d
Number of subjects: 22
Study 6787721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 31838256 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-guided therapy (Group G)
Number of subjects: 1500
Study 31838256 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Group S)
Number of subjects: 1500
Study 30185920 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Number of subjects: 141
Study 30185920 — intervention group
Group type: COMPARATOR
Intervention: Motivational Interviewing (MI)
Number of subjects: 141
Study 28320866 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillotomy (ATT)
Number of subjects: 79
Study 28320866 — intervention group
Group type: COMPARATOR
Intervention: Adenotonsillectomy (ATE)
Number of subjects: 79
Study 25933810 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D model of the cardiac lesion(s) during the appointment
Number of subjects: 103
Study 25933810 — intervention group
Group type: COMPARATOR
Intervention: Routine visit (Control)
Number of subjects: 103
Study 24007198 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Discharge Network Coordination Program
Number of subjects: 160
Study 24007198 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 160
Study 21248399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen phonophoresis and splinting
Number of subjects: 51
Study 21248399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and splinting
Number of subjects: 51
Study 21248399 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound and splinting
Number of subjects: 51
Study 18766393 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory polysomnography (PSG) studies
Number of subjects: 118
Study 17310049 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet (primer)
Number of subjects: 555
Study 17310049 — intervention group
Group type: COMPARATOR
Intervention: General health booklet (control)
Number of subjects: 555
Study 15052213 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-bypassing (group A)
Number of subjects: 64
Study 15052213 — intervention group
Group type: COMPARATOR
Intervention: Single-bypassing (group B)
Number of subjects: 64
Study 11336163 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (EO28 Extra)
Number of subjects: 33
Study 11336163 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric diet (Forticips)
Number of subjects: 33
Study 11336163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (both diets combined)
Number of subjects: 33
Study 11336163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (per-protocol analysis)
Number of subjects: 33
Study 9239583 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms/kg fentanyl i.v. (group 1, n = 10)
Number of subjects: 30
Study 9239583 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg sufentanil i.v. (group 2, n = 10)
Number of subjects: 30
Study 9239583 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg sufentanil i.v. (group 3, n = 10)
Number of subjects: 30
Study 8185029 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with urokinase
Number of subjects: 31
Study 8185029 — intervention group
Group type: COMPARATOR
Intervention: Surgical thrombectomy
Number of subjects: 31
Study 3653859 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (radiotherapy and chemotherapy)
Number of subjects: 25
Study 3653859 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 25
Study 3653859 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (stage II disease)
Number of subjects: 25
Study 29973265 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatments for 4 weeks
Number of subjects: 124
Study 29973265 — intervention group
Group type: COMPARATOR
Intervention: Methycobal
Number of subjects: 124
Study 29231606 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal-cake-separated moxibustion
Number of subjects: 60
Study 29231606 — intervention group
Group type: COMPARATOR
Intervention: Wheat-flour-cake moxibustion
Number of subjects: 60
Study 25660137 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313
Study 25660137 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313
Study 25660137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study 23630244 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic care (enhanced usual care plus individualized care by licensed naturopathic doctors)
Number of subjects: 246
Study 23630244 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 246
Study 22433648 — intervention group
Group type: EXPERIMENTAL
Intervention: Varnish containing CaF(2)
Number of subjects: 0
Study 22433648 — intervention group
Group type: EXPERIMENTAL
Intervention: Varnish 'Bifluorid 12®'
Number of subjects: 0
Study 18215750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic splints
Number of subjects: 15
Study 18215750 — intervention group
Group type: EXPERIMENTAL
Intervention: No splints
Number of subjects: 15
Study 18215750 — intervention group
Group type: EXPERIMENTAL
Intervention: Static splints
Number of subjects: 15
Study 16507926 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane sweeping
Number of subjects: 264
Study 16507926 — intervention group
Group type: COMPARATOR
Intervention: No membrane sweeping
Number of subjects: 264
Study 12835203 — intervention group
Group type: EXPERIMENTAL
Intervention: Food available in à la carte (ALC) areas
Number of subjects: 20
Study 12835203 — intervention group
Group type: EXPERIMENTAL
Intervention: Food available in vending machines (VMs)
Number of subjects: 20
Study 12835203 — intervention group
Group type: COMPARATOR
Intervention: School food policies
Number of subjects: 20
Study 11147619 — intervention group
Group type: EXPERIMENTAL
Intervention: CXR screening
Number of subjects: 37724
Study 8998024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse manager participation in budgeting and staff nurse awareness of costs
Number of subjects: 0
Study 8998024 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of information about clinical behavior and cost savings
Number of subjects: 0
Study 1728831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg once daily
Number of subjects: 3491
Study 1728831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3491
Study 1728831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 3491
Study 6376194 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 363
Study 6376194 — intervention group
Group type: COMPARATOR
Intervention: Pelvic irradiation or FDV
Number of subjects: 363
Study 6376194 — intervention group
Group type: COMPARATOR
Intervention: Whole abdomen + pelvic irradiation or CV or FDV
Number of subjects: 363
Study 6376194 — intervention group
Group type: COMPARATOR
Intervention: FDV, T, and CF
Number of subjects: 363
Study 31254451 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans with knee OA
Number of subjects: 322
Study 31254451 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for demographic and psychological health covariates
Number of subjects: 322
Study 31593273 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of sprifermin administered every 6 months (n=110)
Number of subjects: 549
Study 31593273 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of sprifermin administered every 12 months (n=110)
Number of subjects: 549
Study 31593273 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg of sprifermin administered every 6 months (n=111)
Number of subjects: 549
Study 31593273 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg of sprifermin administered every 12 months (n=110)
Number of subjects: 549
Study 31593273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=108)
Number of subjects: 549
Study 31593273 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of sprifermin (both dosing schedules)
Number of subjects: 549
Study 31593273 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg of sprifermin (both dosing schedules)
Number of subjects: 549
Study 29284503 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaSightTM‐SL tube (VST)
Number of subjects: 46
Study 29284503 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 46
Study 26460537 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (abstinence for one month)
Number of subjects: 185
Study 23354532 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) paired with low energy density yogurt (LED)
Number of subjects: 62
Study 23354532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) paired with low energy density yogurt (LED)
Number of subjects: 62
Study 23354532 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) paired with high energy density yogurt (HED)
Number of subjects: 62
Study 23354532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) paired with high energy density yogurt (HED)
Number of subjects: 62
Study 23354532 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) paired with novel-flavored yogurt
Number of subjects: 62
Study 23354532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) paired with novel-flavored yogurt
Number of subjects: 62
Study 21283001 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum procalcitonin levels measured on day 1 and day 3
Number of subjects: 65
Study 21283001 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in procalcitonin levels on day 3 from baseline
Number of subjects: 65
Study 21283001 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing procalcitonin levels
Number of subjects: 65
Study 21283001 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic multilobar disease
Number of subjects: 65
Study 19729375 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose lopinavir/ritonavir
Number of subjects: 24
Study 19729375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lopinavir/ritonavir
Number of subjects: 24
Study 16566424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules (twice daily 500 mg)
Number of subjects: 560
Study 16566424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lactobacilli (twice daily a capsule with > 10^9 colony-forming units of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Number of subjects: 560
Study 16566424 — intervention group
Group type: COMPARATOR
Intervention: Standardised antibiotic therapy (once daily 480 mg trimethoprim-sulfamethoxazole)
Number of subjects: 560
Study 16566424 — intervention group
Group type: COMPARATOR
Intervention: Standardised antibiotic therapy
Number of subjects: 560
Study 12846539 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐GSA SPECT
Number of subjects: 137
Study 11044270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined artesunate-praziquantel
Number of subjects: 110
Study 11044270 — intervention group
Group type: COMPARATOR
Intervention: Artesunate alone
Number of subjects: 110
Study 11044270 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel alone
Number of subjects: 110
Study 8973673 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.8-mg goserelin acetate depot every 12 weeks
Number of subjects: 160
Study 8973673 — intervention group
Group type: COMPARATOR
Intervention: 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks, then 10.8-mg depot every 12 weeks thereafter
Number of subjects: 160
Study 8973673 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.8-mg goserelin acetate depot
Number of subjects: 160
Study 8973673 — intervention group
Group type: COMPARATOR
Intervention: 3.6-mg goserelin acetate depot
Number of subjects: 160
Study 8973673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both depots
Number of subjects: 160
Study 1478032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum constriction-band device (Erecaid)
Number of subjects: 39
Study 1478032 — intervention group
Group type: COMPARATOR
Intervention: Condom-type device (Synergist)
Number of subjects: 39
Study 6363220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg daily: 50 mg before breakfast and before evening meal)
Number of subjects: 254
Study 6363220 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1000 mg daily: 200 mg with breakfast, lunch, and evening meal, and 400 mg at bedtime)
Number of subjects: 254
Study 6363220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 254
Study 6363220 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 254
Study 31091567 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia instruction
Number of subjects: 123
Study 31091567 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 123
Study 29734180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (PRN regimen)
Number of subjects: 64
Study 29734180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly regimen)
Number of subjects: 64
Study 29734180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (T&E regimen)
Number of subjects: 64
Study 29734180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (overall)
Number of subjects: 64
Study 26979080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin strut biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 2119
Study 26979080 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stent (DP-EES)
Number of subjects: 2119
Study 26979080 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 2119
Study 26979080 — intervention group
Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 2119
Study 25082724 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective repeat cesarean delivery (ERCD)
Number of subjects: 212
Study 25082724 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of labor (TOL)
Number of subjects: 212
Study 25082724 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty about preferred mode of birth
Number of subjects: 212
Study 22217510 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose 17β-estradiol/norethisterone acetate (NETA)
Number of subjects: 24
Study 22217510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 24
Study 22217510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 17β-estradiol/NETA
Number of subjects: 24
Study 22217510 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene hydrochloride
Number of subjects: 24
Study 20171140 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (DO) 4 mg/day for 2 weeks, then 8 mg/day for 2 weeks
Number of subjects: 16
Study 20171140 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (DO)
Number of subjects: 16
Study 20171140 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (EN) 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks
Number of subjects: 16
Study 20171140 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (EN)
Number of subjects: 16
Study 20171140 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (DO) and Enalapril (EN)
Number of subjects: 16
Study 17364528 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 0